Source comparison
Comparison: Thymosin Alpha-1 vs Other Immune-Modulating Peptides in Cancer Care
Thymosin Alpha-1 TLR-2/TLR-9 activation, IL-2 upregulation, dendritic cell maturation 1.6mg SC twice weekly CD4+ increase visible at 7-10 days; NK cell activity up 18-25% at week 2 Reduced infection rates at 4-8 weeks; tumor marker response at 8-12 weeks if pr
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR-2/TLR-9 activation, IL-2 upregulation, dendritic cell maturation
- 1.6mg SC twice weekly
- CD4+ increase visible at 7-10 days; NK cell activity up 18-25% at week 2
- Reduced infection rates at 4-8 weeks; tumor marker response at 8-12 weeks if present
- Hepatocellular carcinoma (Phase III survival benefit); NSCLC chemotherapy adjunct (Phase II infection reduction)
- Thymalin
- Thymic peptide complex, broader immune restoration
- 10mg IM daily × 5-10 days
- Generalized immune recovery slower. Measurable at 14-21 days
- Less defined; primarily used in post-infection recovery rather than active cancer
- Limited to observational studies; no Phase III cancer data
- LL-37 (Cathelicidin)
- Antimicrobial peptide with anti-tumor properties via apoptosis induction
- Experimental dosing varies
- Direct cytotoxic effect on some cancer cell lines in vitro
- No established clinical timeline. Still in preclinical models
- Promising in vitro data; no human cancer trials published
- Epithalon
- Telomerase modulation, potential anti-aging effect
- 10mg SC daily × 10 days, cycled
- Theoretical immune benefit via cellular senescence reduction
- No validated cancer-specific outcomes
- No peer-reviewed cancer trials; mechanism unproven in oncology context
- Professional Assessment
- Tα1 has the strongest clinical evidence for cancer adjunct use. Particularly in hepatocellular carcinoma and as a chemotherapy side-effect mitigator. Thymalin offers broader thymic support but lacks Phase III cancer data. LL-37 and Epithalon remain experimental without established dosing or outcomes in human oncology.
- For researchers seeking immune-modulating peptides beyond Tα1, our full peptide collection includes research-grade synthesis with third-party purity verification.